Oncology Today with Dr Neil Love

Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
Managing brain metastases in triple-negative breast cancer (6:30)
EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)
PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)

CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)
Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)

CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:
Introduction (0:00)
Minimal Residual Disease Assays in Community-Based Practice (1:24)
New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
Richter Transformation (30:43)
Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:
Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00)
Case: A woman in her mid 50s with ovarian cancer and a genomic instability score of 50, folate receptor alpha 90%, HER2 IHC 2+, and BRCA1/2 wild-type disease treated initially with surgery, carboplatin/paclitaxel and maintenance olaparib/bevacizumab — Dr Ursula Matulonis (8:46)

CME information and select publications

Featuring an interview with Dr L Elizabeth Budde, including the following topics:
Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications